

INTERCEPT PHARMACEUTICALS INC  
Form 8-K  
December 01, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 1, 2015**

**INTERCEPT PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

|  |                     |                            |
|--|---------------------|----------------------------|
| <b>Delaware</b><br><b>(state or other jurisdiction</b>                       | <b>001-35668</b>    | <b>22-3868459</b>          |
| <b>of incorporation)</b>   | <b>(Commission</b>  | <b>(I.R.S. Employer</b>    |
|  | <b>File Number)</b> | <b>Identification No.)</b> |
| <b>450 W. 15<sup>th</sup> Street, Suite 505</b>                              |                     | <b>10011</b>               |
| <b>New York, New York</b><br><b>(Address of principal executive offices)</b> |                     | <b>(Zip Code)</b>          |

**Registrant's telephone number, including area code: (646) 747-1000**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

As previously announced during the third quarter 2015 financial results call on November 9, 2015, Intercept Pharmaceuticals, Inc. will be holding an analyst and investor event on December 1, 2015 at 9:00 am ET. The live event will be available via webcast on the investor page of Intercept's website at <http://ir.interceptpharma.com>. A replay of the webcast will be available on Intercept's website approximately two hours after the completion thereof and will be archived for two weeks.

The slides to be presented at the event are attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B-2 of Form 8-K, the information set forth in or incorporated by reference into this Item 7.01 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

99.1 Slides for Analyst and Investor Event held on December 1, 2015.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERCEPT PHARMACEUTICALS, INC.

Dated: December 1, 2015 /s/ Mark Pruzanski  
Mark Pruzanski, M.D.

President and Chief Executive Officer